EGFR and breast carcinoma: Further, a recent high throughput screen using breast cancer PDX models with PI3K mutations found that afatinib and alpelisib were synergistic, which confirms our data, however they did not compare the synergy of models with both EGFR amplification and PI3K mutations to those without [35].